Patients
A total of 692 patients with PDAC who underwent curative resection in
the Department of Pancreatic Cancer, Tianjin Medical University Cancer
Institute and Hospital between January 2011 and December 2018 were
eligible for this study. Eligibility criteria included: (I) patients
with PDAC; (II) patients with R0 resection; (III) patients who were
completely followed up. Exclusion criteria included: (I) patients with
history of pancreatectomy or other malignancy; (II) patients with
arterial tumor contact (celiac axis, superior mesenteric artery, or
common hepatic artery); (III) patients with distant metastasis; (V)
patients who accepted neoadjuvant chemotherapy; (VI) patients who died
during the initial hospital stay or 1 month after surgery. After
excluding 10 patients with pancreatic mucinous carcinoma, 9 patients
with pancreatic adenosquamous carcinoma, 1 patient with lung cancer, 1
patient with gastric cancer, 3 patients with breast cancer, 10 patients
with R1 resection, 1 patient with R2 resection, 14 patients confirmed
with distant metastasis during laparotomy, 22 patients lost, 4 patients
accepted neoadjuvant chemotherapy, 2 patients died during the initial
hospital stay and 3 patients died within 1 month after surgery,
ultimately, 612 patients were included in this study.